Diagnostic pre-clinical services program -IDIQ - dynport
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N93023D00016
- Awardee
-
Dynport Vaccine Company LLC UEI LXNEGTYDR755
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Task orders
- 3 $10,500 obligated
Award facts
- Opportunity
-
- Diagnostics pre-clinical services program Pre-Solicitation · Posted Dec 21, 2021
- Combined order value
- $10,500 Current and potential, with all options
- Last date to order 48% complete
- IDV ceiling <1% used
- $36,000,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 12 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Institute of Allergy and Infectious Diseases awarded a single-award IDIQ to Dynport Vaccine Company LLC on June 20, 2023, with a ceiling of $36 million and a completion date of June 19, 2030. The contract supports the development of diagnostic products for infectious disease detection, identification, and characterization through preclinical research and advancement services.
Place of performance is Frederick, Maryland. The IDIQ funds research, development, manufacturing, and testing services including assay validation, pilot manufacturing, process development, and regulatory documentation to bring candidate infectious disease diagnostics to market.
The originating pre-solicitation, posted in December 2021, anticipated awarding multiple IDIQs for a seven-year period beginning in June 2023 under NAICS 541711 and PSC D399. The agency sought capability statements from organizations with experience in product development processes, reagent provision, biological material handling, and safety procedures.
Task order activity under this IDIQ includes firm fixed price delivery orders at $3,500 each issued to support diagnostic product development, with work performed at Dynport's Frederick, Maryland facility. The contract carries no set-aside designation.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N93023D00016?
75N93023D00016 was awarded to Dynport Vaccine Company LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 20, 2023.
How much is contract 75N93023D00016 worth?
Orders under 75N93023D00016 have obligated $10,500. 75N93023D00016's own ceiling is $36,000,000.
How many orders have been placed under contract 75N93023D00016?
3 orders have been placed under 75N93023D00016, the latest on June 20, 2023.
Who can order from contract 75N93023D00016?
75N93023D00016 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N93023D00016 competed?
The extent of competition for 75N93023D00016 was full and open competition. The government received 12 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV